US20150216778A1 - Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof - Google Patents
Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof Download PDFInfo
- Publication number
- US20150216778A1 US20150216778A1 US14/373,274 US201314373274A US2015216778A1 US 20150216778 A1 US20150216778 A1 US 20150216778A1 US 201314373274 A US201314373274 A US 201314373274A US 2015216778 A1 US2015216778 A1 US 2015216778A1
- Authority
- US
- United States
- Prior art keywords
- galactose
- acid
- anhydro
- agarose
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 title claims abstract description 132
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 title claims abstract description 126
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical compound O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000002087 whitening effect Effects 0.000 claims abstract description 25
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims description 42
- 108090000790 Enzymes Proteins 0.000 claims description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 239000002537 cosmetic Substances 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 24
- 229920000936 Agarose Polymers 0.000 claims description 22
- 108010046109 neoagarobiose hydrolase Proteins 0.000 claims description 19
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 14
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 208000012641 Pigmentation disease Diseases 0.000 claims description 9
- 230000019612 pigmentation Effects 0.000 claims description 9
- 208000003351 Melanosis Diseases 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000031019 skin pigmentation disease Diseases 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 206010008570 Chloasma Diseases 0.000 claims description 4
- 206010014970 Ephelides Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000007256 Nevus Diseases 0.000 claims description 3
- 208000000069 hyperpigmentation Diseases 0.000 claims description 3
- 230000003810 hyperpigmentation Effects 0.000 claims description 3
- 206010024217 lentigo Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 15
- 239000000126 substance Substances 0.000 abstract description 14
- 150000002772 monosaccharides Chemical class 0.000 abstract description 10
- 238000006911 enzymatic reaction Methods 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 230000001766 physiological effect Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 229920001817 Agar Polymers 0.000 abstract description 2
- 239000008272 agar Substances 0.000 abstract description 2
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 36
- 102000003425 Tyrosinase Human genes 0.000 description 27
- 108060008724 Tyrosinase Proteins 0.000 description 27
- 230000000694 effects Effects 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 22
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 18
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 15
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 14
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 12
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 11
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 11
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 11
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 11
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- WZYRMLAWNVOIEX-BGPJRJDNSA-N 3,6-anhydro-D-galactose Chemical compound O=C[C@H](O)[C@H]1OC[C@@H](O)[C@@H]1O WZYRMLAWNVOIEX-BGPJRJDNSA-N 0.000 description 10
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 10
- 101710200814 Melanotropin alpha Proteins 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001670248 Saccharophagus degradans Species 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 7
- 150000002016 disaccharides Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- IBZYPBGPOGJMBF-UHFFFAOYSA-N 3,6 anhydrogalactose Natural products CCC=CCC1C(CC(=O)NC(C(C)CC)C(O)=O)CCC1=O IBZYPBGPOGJMBF-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 229960000271 arbutin Drugs 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000000968 medical method and process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DCQFFOLNJVGHLW-ZUEQSLHLSA-N [H]C12CO[C@@]([H])(C([H])(O)[C@@]([H])(O)O1)[C@]2([H])O Chemical compound [H]C12CO[C@@]([H])(C([H])(O)[C@@]([H])(O)O1)[C@]2([H])O DCQFFOLNJVGHLW-ZUEQSLHLSA-N 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000005377 adsorption chromatography Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007515 enzymatic degradation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241001170685 Saccharophagus degradans 2-40 Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 2
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000007073 chemical hydrolysis Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002065 hypopigmenting effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101150056978 HMGS gene Proteins 0.000 description 1
- 101150027313 Has2 gene Proteins 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 101100011891 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERG13 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000003764 chromatophore Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- NONFLFDSOSZQHR-CQOLUAMGSA-N d4-trimethyl silyl propionic acid Chemical compound OC(=O)C([2H])([2H])C([2H])([2H])[Si](C)(C)C NONFLFDSOSZQHR-CQOLUAMGSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 201000007909 oculocutaneous albinism Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/10—Anhydrosugars, e.g. epoxides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01159—Alpha-neoagaro-oligosaccharide hydrolase (3.2.1.159)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Definitions
- the present invention relates to 3,6-anhydro-L-galactose prepared through chemical and enzymatic methods and industrial use thereof using physiological efficacy.
- Agar (or agarose) which is a main polysaccharide constituting a red alga is a polymer in which two monosaccharides, 3,6-anhydro-L-galactose and D-galactose, are alternately bound via ⁇ -1,3 linkage and ⁇ -1,4 linkage. It has been widely known in that an agarooligosaccharide produced by non-specifically hydrolyzing agarose using a chemical catalyst such as hydrochloric acid, sulfuric acid, and acetic acid exhibits excellent physiological activities such as antioxidant, anti-inflammatory, anti-cancer, whitening, and anti-allergic activities. Due to a variety of such physiological activities, agarooligosaccharides and neoagarobiose that are disaccharides have been widely used as functional materials in the fields of food and beauty industries.
- 3,6-anhydro-L-galactose has problems in that it is produced as a monosaccharide with a very low yield through conventional chemical treatments, and is easily degraded to excessive extents since it has an unstable reducing end and is easily converted into hydroxymethylfurfural in the presence of a high-concentration strong acid under high-temperature reaction conditions (Jol et al (1999) Anal Biochem. 268, 213-222, Kim et al (2010) Bull Korean Soc. 31(2) 511-514).
- the hydrolysis using chemical treatment has an advantage in that it is readily applicable for the purpose of commercialization due to low production cost and simple treatment conditions, it has a problem in that a desired product is produced with a very low yield when specific linkages are broken to obtain the product since the chemical treatment non-specifically breaks the linkages (Chen et al (2005) Food Technol Biotechnol. 43(1) 29-36). Further, enzymes specifically breaking linkages in 3,6-anhydro-L-galactose to produce monosaccharides have been reported in recent years, but studies remain to be done to separate, purify, and quantify only 3,6-anhydro-L-galactose from a reaction product.
- the present invention is directed to a method for preparing 3,6-anhydro-L-galactose with a high yield through enzymatic degradation while minimizing over-degradation effects caused by chemical treatment.
- the present invention is directed to industrial use thereof to investigate the physiological activities of 3,6-anhydro-L-galactose.
- a method for preparing 3,6-anhydro-L-galactose which includes preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours, and allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
- the agarose-degrading enzyme may be an enzyme that breaks a ⁇ -1,4-glycosidic linkage between D-galactose and 3,6-anhydro-L-galactose of agarose. More specifically, the agarose-degrading enzyme may be represented by an amino acid sequence set forth in SEQ ID NO: 1.
- the neoagarobiose hydrolase may be represented by an amino acid sequence set forth in SEQ ID NO: 3.
- the agarose-degrading enzyme and the neoagarobiose hydrolase may be derived from Saccharophagus degradans ( S. degradans ) 2-40.
- the method for preparing 3,6-anhydro-L-galactose may further include separating and purifying the 3,6-anhydro-L-galactose by sequentially performing adsorption chromatography and gel-permeation chromatography on the 3,6-anhydro-L-galactose.
- a cosmetic composition for skin whitening or moisturizing including 3,6-anhydro-L-galactose.
- a pharmaceutical composition for preventing or treating a skin pigmentation disease including 3,6-anhydro-L-galactose.
- a cosmetic or medical method for whitening or moisturizing a skin of a mammal preferably, a human, which requires skin whitening or moisturizing.
- the cosmetic or medical method includes administering an effective amount of 3,6-anhydro-L-galactose, preferably, a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose.
- a cosmetic or medical method for treating a condition, disease, and/or lesion of the skin associated with regulation of pigmentation includes applying a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose onto the skin, and the condition, disease, and/or lesion may be locally advanced due to an increase in synthesis of a melanin pigment, and may be at least one selected from the group consisting of chloasma, freckles, lentigo, nevi, pigmentation caused by use of drugs, post-inflammatory pigmentation, and hyperpigmentation occurring on dermatitis.
- a pharmaceutical composition for preventing or treating an inflammatory disease which includes 3,6-anhydro-L-galactose.
- the method includes administering the composition for preventing or treating an inflammatory disease, which includes a pharmaceutically effective amount of 3,6-anhydro-L-galactose, to a subject.
- FIG. 1 is a diagram illustrating a procedure of preparing 3,6-anhydro-L-galactose from agarose according to one exemplary embodiment of the present invention.
- DP represents a degree of polymerization of a polysaccharide.
- FIG. 2 shows the thin-layer chromatography (TLC) results obtained in a procedure of preparing and purifying 3,6-anhydro-L-galactose from agarose.
- Lane 1 represents agarose
- Lane 2 represents an acetic acid hydrolysate
- Lane 3 represents an Aga50D reaction product
- Lane 4 represents a sdNABH reaction product
- Lane 5 represents 3,6-anhydro-L-galactose separated by silica gel chromatography
- Lane 6 represents 3,6-anhydro-L-galactose purified by biogel P2 chromatography
- AHG in the Y axis represents 3,6-anhydro-galactose
- NAB represents neoagarobiose.
- FIG. 3 shows the results of silica gel chromatography-TLC which is the first step of purifying 3,6-anhydro-L-galactose.
- AHG represents 3,6-anhydro-galactose.
- FIG. 4 shows GC/MS total ion chromatograms of (a) a D-form 3,6-anhydro-galactose standard material and (b) 3,6-anhydro-L-galactose purified according to one exemplary embodiment of the present invention.
- FIG. 5 shows the 1 H NMR analysis results of 3,6-anhydro-L-galactose separated and purified according to one exemplary embodiment of the present invention.
- FIG. 6 shows the 2D-HSQC NMR analysis results of 3,6-anhydro-L-galactose separated and purified according to one exemplary embodiment of the present invention.
- FIG. 7 shows the whitening activities of 3,6-anhydro-L-galactose, neoagarobiose, D-galactose, and 3,6-anhydro-D-galactose.
- ⁇ -MSH represents an ⁇ -melanocyte-stimulating hormone
- NAB represents neoagarobiose
- D-AHG and L-AHG represent D- and L-forms of 3,6-anhydro-galactose, respectively.
- FIG. 8 shows the antioxidant activities of 3,6-anhydro-L-galactose, neoagarobiose, D-galactose, and 3,6-anhydro-D-galactose.
- FIG. 9 shows effects of L-AHG on expression of tyrosinase induced by ⁇ -MSH in HEMs.
- FIG. 9A shows the results of tyrosinase expression in the cells exposed to ⁇ -MSH after treatment according to concentrations of L-AHG
- FIG. 9B shows a graph obtained by plotting the results of FIG. 9A as relative intensity of tyrosinase to ⁇ -actin.
- FIG. 10 shows effects of L-AHG on expression of TRP-1 induced by ⁇ -MSH in HEMs.
- FIG. 10A shows the results of TRP-1 expression in the cells exposed to ⁇ -MSH after treatment according to concentrations of L-AHG
- FIG. 10B shows a graph obtained by plotting the results of FIG. 10A as relative intensity of TRP-1 to ⁇ -actin.
- FIG. 11 shows effects of L-AHG on in vitro tyrosinase activities.
- FIG. 12 shows effects of L-AHG on expression of HAS2 in human corneous cells.
- FIG. 12A shows an expression level of HAS2 after treatment with 100 ⁇ g/mL of L-AHG according to the elapse of time
- FIG. 12B shows an expression level of HAS2 after treatment according to concentrations of L-AHG
- FIG. 13 shows effects of L-AHG on phosphorylation of ERK in human corneous cells.
- FIG. 13A shows the ERK phosphorylation results after treatment with 100 ⁇ g/mL of L-AHG according to the elapse of time
- FIG. 13B shows the ERK phosphorylation results after treatment according to concentrations of L-AHG
- FIG. 14 shows effects of L-AHG on phosphorylation of AKT in human corneous cells.
- FIG. 14A shows the AKT phosphorylation results after treatment with 100 ⁇ g/mL of L-AHG according to the elapse of time
- FIG. 14B shows the AKT phosphorylation results after treatment according to concentrations of L-AHG
- the present invention is directed to a method for preparing 3,6-anhydro-L-galactose, which includes preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours, and allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
- the method for preparing 3,6-anhydro-L-galactose is characterized in that agarose is hydrolyzed under mild conditions using a weak acid, an agarooligosaccharide separated from the acid hydrolysate is allowed to react with an exo-type agarose-degrading enzyme producing disaccharides to produce a neoagarobiose, and monosaccharides, galactose and 3,6-anhydro-L-galactose, are produced through additional reaction with a neoagarobiose hydrolase.
- the 3,6-anhydro-L-galactose may have a structure represented by the following Formula 1:
- the first step is to prepare an agarooligosaccharide by treating agarose with a weak acid.
- the weak acid may be at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid, which may be used alone or in combination.
- the weak acid may be used at a concentration of 0.5 to 60% (w/v) in consideration of the unit production cost of and separation of salts produced after neutralization of weak acid. More specifically, the weak acid may be used at a concentration of 20 to 40% (w/v).
- the reaction of the weak acid with the agarose may be performed at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours. Within these ranges, formation of over-degradation products of agarose by the weak acid may be minimized.
- the reaction product obtained after the reaction is an agarooligosaccharide which may be washed to remove the over-degradation product with the residual weak acid, and dried so that the agarooligosaccharide can be obtained in a powdery form.
- washing solvent a lower alcohol having 1 to 6 carbon atoms may be used, but the present invention is not limited thereto.
- the second step is to prepare 3,6-anhydro-L-galactose by enzymatic degradation of the agarooligosaccharide.
- the enzymatic degradation is performed by producing a disaccharide, neoagarobiose, by treating the agarooligosaccharide with an exo-type agarose-degrading enzyme and degrading the neoagarobiose into D-galactose and 3,6-anhydro-L-galactose by treating the neoagarobiose with a neoagarobiose hydrolase.
- the enzymatic reaction may be performed at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
- an enzyme breaking a ⁇ -1,4-glycosidic linkage between D-galactose and 3,6-anhydro-L-galactose of agarose (hereinafter referred to as ‘Aga50D’) may be used as the agarose-degrading enzyme degrading the agarooligosaccharide to produce the disaccharide, neoagarobiose.
- the agarose-degrading enzyme may include an amino acid sequence set forth in SEQ ID NO: 1, and amino acid sequences having sequence identities of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with respect to the amino acid sequence.
- a polypeptide having a sequence identity of certain percentage (for example, 80%, 85%, 90%, 95%, or 99%) with respect to another sequence means that two sequences has the same amino acid residues at any percentage upon sequence comparison when the sequences are aligned to each other.
- the alignment and percentage homology or identity may be determined using any proper software program known in the related art, for example, those described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al., (eds) 1987 Supplement 30 section 7.7.18).
- a preferred program includes GCG Pileup programs, for example FASTA (Pearson, et al., 1988 Proc. Natl. Acad. Sci.
- BLAST BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med. (NCIB NLM NIH), Bethesda, Md., and Altschul et al., 1997 NAR25: 3389-3402).
- Another preferred alignment program is ALIGN Plus (Scientific and Educational Software, PA), which preferably uses basic parameters.
- Still another preferred sequence software program which may be used herein is a TFASTA Data Searching program available for Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison Wis.).
- the enzyme may be derived from S. degradans 2-40, but the present invention is not limited thereto.
- the enzyme may be transcribed and translated through a coding gene, that is, a DNA fragment which is associated with production of a polypeptide including regions upstream and downstream of a coding region of the enzyme and an intervening sequence between individual coding fragments.
- a coding gene that is, a DNA fragment which is associated with production of a polypeptide including regions upstream and downstream of a coding region of the enzyme and an intervening sequence between individual coding fragments.
- the enzyme may have a sequence set forth in SEQ ID NO: 2, but the present invention is not limited thereto.
- the agarose-degrading enzyme according to one exemplary embodiment of the present invention may be separated and purified from a supernatant of the S. degradans culture broth, and may be produced and separated in the strains other than S. degradans using a genetic recombination technique or an artificial chemical synthesis method.
- a supernatant of the S. degradans culture broth may be used instead of the agarose-degrading enzyme according to one exemplary embodiment of the present invention, or a supernatant of a culture broth of an edible strain, for example, a transformed yeast strain obtained by transforming a yeast strain, may be used instead of the agarose-degrading enzyme.
- the term “recombination” used in connection with cells, nucleic acids, proteins, or vectors means that the cells, nucleic acids, proteins, or vectors are modified by introduction of heterogeneous nucleic acids or proteins or alteration of innate nucleic acids or proteins, or that the cells are derived from such modified cells. That is, the recombinant cells, for example, express genes which are not found in the cells in an original non-recombinant form, or express original genes which are expressed abnormally upon expression or not expressed at all.
- nucleic acid encompasses all kinds of single- or double-stranded DNAs, RNAs, and chemical variants thereof.
- nucleic acid and polynucleotide may be used interchangeably herein. Since the genetic codes are degenerated, one or more codons may be used to encode one certain amino acid, and the present invention covers polynucleotides encoding certain amino acid sequences.
- introduction used to insert a nucleic acid sequence into cells refers to “transfection,” “transformation,” or “transduction,” and encompasses reference to integration of a nucleic acid sequence into eucaryotic or procaryotic cells.
- the nucleic acid sequence is integrated into the genome (for example, a chromosome, a plasmid, a chromatophore, or mitochondrial DNA) of a cell, and converted into an autonomous replicon or expressed temporally.
- the reaction of the agarooligosaccharide with the agarose-degrading enzyme may be performed at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days. More specifically, such a reaction may be performed at a temperature of 25 to 35° C. and a rotary speed of 100 to 150 rpm for 1 to 4 days.
- the agarooligosaccharide When the agarooligosaccharide is in a powdery form, the agarooligosaccharide may be dissolved in a conventional buffer solution to be used, but the present invention is not limited thereto.
- the neoagarobiose hydrolase that can degrade the neoagarobiose produced through the enzymatic reaction into D-galactose and 3,6-anhydro-L-galactose may be a protein having an amino acid sequence set forth in SEQ ID NO: 3 and a mutant protein having at least one substitution, deletion, translocation, and addition in the enzyme.
- Proteins having the neoagarobiose-hydrolytic activities are also included in a category of the enzymes according to one exemplary embodiment of the present invention, and, preferably, has an amino acid sequence having a sequence identity of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with respect to the amino acid sequence set forth in SEQ ID NO: 3 (hereinafter referred to as ‘sdNABH’).
- the enzyme may be derived from S. degradans 2-40, but the present invention is not limited thereto.
- the enzyme may be transcribed and translated through a coding gene, that is, a DNA fragment which is associated with production of a polypeptide including regions upstream and downstream of a coding region of the enzyme and an intervening sequence between individual coding fragments.
- a coding gene that is, a DNA fragment which is associated with production of a polypeptide including regions upstream and downstream of a coding region of the enzyme and an intervening sequence between individual coding fragments.
- the enzyme may have a sequence set forth in SEQ ID NO: 4, but the present invention is not limited thereto.
- the neoagarobiose hydrolase may be separated and purified from a supernatant of the S. degradans culture broth, and may be produced and separated in the strains other than S. degradans using a genetic recombination technique or an artificial chemical synthesis method.
- a supernatant of the S. degradans culture broth may be used instead of the neoagarobiose hydrolase according to one exemplary embodiment of the present invention, or a supernatant of a culture broth of an edible strain, for example, a transformed yeast strain obtained by transforming a yeast strain, may be used instead of the neoagarobiose hydrolase.
- the reaction of the neoagarobiose with the neoagarobiose hydrolase may be performed at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days. More specifically, such a reaction may be performed at a temperature of 25 to 35° C. and a rotary speed of 100 to 150 rpm for 1 to 4 days.
- the method for preparing 3,6-anhydro-L-galactose according to one exemplary embodiment of the present invention may further include separating and purifying only 3,6-anhydro-L-galactose from the degradation products of neoagarobiose.
- the 3,6-anhydro-L-galactose may be separated and purified with a high purity of approximately 96% by sequentially performing silica gel chromatography that is adsorption chromatography and biogel P2 chromatography that is gel-permeation chromatography.
- the purified product is subjected to 1 H-NMR and 2D-heteronuclear single quantum coherence (HSQC) NMR analysis, and 1 H ppm and 13 C ppm of previously reported 3,6-anhydro-L-galactose may be compared to identify the structure of the purified product.
- HSQC single quantum coherence
- 76 g of the agarooligosaccharide may be produced from 100 g of agarose through chemical hydrolysis, and 37.55 g of the neoagarobiose and 15.21 g of the 3,6-anhydro-L-galactose may be produced using the Aga50D and sdNABH enzymes, respectively. Also, 3.98 g of pure 3,6-anhydro-L-galactose may be purified through a purification procedure using two kinds of chromatographies.
- the present invention is also directed to a cosmetic composition for skin whitening or moisturizing including 3,6-anhydro-L-galactose.
- the present invention is directed to cosmetic use of 3,6-anhydro-L-galactose for skin whitening or moisturizing.
- the 3,6-anhydro-L-galactose has higher whitening activities than arbutin that has been most widely known as a conventional whitening material, and has an effect of inhibiting the expression of tyrosinase, TRP-1, and the like, which are associated with promoting synthesis of melanin, in a concentration-dependent manner.
- an in vitro tyrosinase activity test shows that the 3,6-anhydro-L-galactose exhibits a whitening effect by inhibiting expression of the enzyme rather than inhibiting the tyrosinase activities.
- the 3,6-anhydro-L-galactose has an effect of promoting the expression of a HAS2 protein that is a moisturizing marker associated with the synthesis of hyaluronic acid.
- the expression of the HAS2 protein may be regulated by various inflammatory signal transduction pathways such as ERK, and AKT.
- ERK e.g., ERK
- AKT e.g., ERK, KCl
- the 3,6-anhydro-L-galactose may increase phosphorylation of ERK and AKT
- the highly phosphorylated ERK and AKT may increase the expression of the HAS2 protein.
- the 3,6-anhydro-L-galactose may be used without limitation as long as it may be synthesized, or may be prepared using the method for preparing 3,6-anhydro-L-galactose according to one exemplary embodiment of the present invention.
- a cosmetic preparation or cosmetics including the 3,6-anhydro-L-galactose itself or a mixture obtained by mixing a cosmetologically acceptable carrier with the 3,6-anhydro-L-galactose may be provided.
- the cosmetic preparation or cosmetics may be prepared into typical emulsified and solubilized formulations.
- the cosmetics may include a lotion, a cream, an essence, and the like, and, in the solubilized formulation, the cosmetics may be a toner.
- Proper formulations of the cosmetics may, for example, be provided in the form of a solution, a gel, a solid or pasty anhydrous product, an emulsion obtained by dispersing an oily phase in a water phase, a suspension, a microemulsion, a microcapsule, a microgranulocyte, or an ionic (liposomal) or non-ionic vesicle dispersing agent, or may also be provided in the form of a cream, a toner, a lotion, a powder, an ointment, a spray, or a conceal stick.
- formulations of the cosmetics may be prepared in the form of a foam or an aerosol composition further including a compressed propellant.
- the cosmetics may include supplemental agents typically used in the field of cosmetology, such as a fat material, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizing agent, a foaming agent, an aromatic, a surfactant, water, an ionic or non-ionic emulsifying agent, a filler, a metal ion sequestering and chelating agent, a preservative, a vitamin, a blocking agent, a moisturizing agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic activating agent, a lipid vesicle, or any other components typically used in cosmetics.
- supplemental agents typically used in the field of cosmetology such as a fat material, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, a softening agent, an antioxidant, a suspending agent,
- the 3,6-anhydro-L-galactose When used for foods or as a food additive, the 3,6-anhydro-L-galactose itself may be added, or may be used in connection with other foods or food components. In this case, the 3,6-anhydro-L-galactose may be properly used according to conventional methods.
- the amount of the mixed active component may be determined according to a purpose of use (prophylaxis, health, or therapeutic treatment). In general, the composition according to one exemplary embodiment of the present invention may be added at a content of 15 wt % or less, preferably 10 wt % or less, based on the total amount of the active component, upon preparation of foods.
- the amount of the mixed active component may be lower than or equal to the above-described content.
- the active component may also be used within this content range or less.
- the present invention is also directed to a pharmaceutical composition for preventing or treating a skin pigmentation disease, which includes 3,6-anhydro-L-galactose.
- the present invention is directed to use of the 3,6-anhydro-L-galactose for preparing the pharmaceutical composition for preventing or treating a skin pigmentation disease.
- the pharmaceutical composition according to one exemplary embodiment of the present invention may further include a suitable carrier, excipient, and diluent which are typically used to prepare pharmaceutical compositions.
- the pharmaceutical composition according to one exemplary embodiment of the present invention may be formulated in the form of external preparations such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, syrup, and an aerosol, and in the form of a sterile injectable solution according to conventional methods.
- the pharmaceutical composition may be used in the form of a cream, a gel, a patch, a spraying agent, an ointment, a plaster, a lotion, a liniment, a paste, or a cataplasma.
- the carrier, excipient, and diluent that may be included in the pharmaceutical composition according to one exemplary embodiment of the present invention may include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.
- the pharmaceutical composition may be prepared using a diluent or excipient widely used in the related art, such as a filler, an extending agent, a binding agent, a wetting agent, a disintegrating agent, a surfactant, and the like.
- a diluent or excipient widely used in the related art, such as a filler, an extending agent, a binding agent, a wetting agent, a disintegrating agent, a surfactant, and the like.
- a solid preparation for oral administration may include a tablet, a pill, a powder, a granule, a capsule, and the like. Such a solid preparation may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, or gelatin, with the above-described compound. In addition to the simple excipients, lubricants such as magnesium stearate and talc may also be used.
- a liquid preparation for oral administration may include a suspension, a liquid for internal use, an emulsion, syrup, and the like.
- the liquid preparation may include various excipients, for example, a wetting agent, a sweetening agent, an aromatic, a preservative, and the like.
- a preparation for parenteral administration may include a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, a suppository, and the like.
- a vegetable oil such as propylene glycol, polyethylene glycol, or olive oil, or an injectable ester such as ethyl oleate may be used as the non-aqueous solvent and the suspension.
- Witepsol, Macrogol, Tween 61, cocoa butter, laurin butter, glycerogelatin, and the like may be used as base of the suppository.
- the pharmaceutical composition according to one exemplary embodiment of the present invention may be a formulation for external use in the skin which can be applied to the skin.
- the pharmaceutical composition may be prepared in the form of a liquid for external use, such as a cream, a gel, a patch, a spraying agent, an ointment, a plaster, a lotion, a liniment, a paste, or a cataplasma, but the present invention is not limited thereto.
- a desirable dose of the pharmaceutical composition according to one exemplary embodiment of the present invention may vary according to the conditions and body weight of a patient, the severity of a disease, the type of a drug, and the route and duration of administration, but may be properly chosen by those skilled in the related art.
- the composition according to one exemplary embodiment of the present invention may be administered daily at a dose of 0.0001 to 100 mg/kg, preferably 0.001 to 10 mg/kg, in order to show a desirable medicinal effect.
- the liquid for external use may be administered once or several times a day. The dosage is not intended to limit the scope of the present invention at any aspects.
- the present invention is directed to a cosmetic or medical method for whitening or moisturizing a skin of a mammal, preferably, a human, which requires skin whitening or moisturizing.
- the cosmetic or medical method includes administering an effective amount of 3,6-anhydro-L-galactose, preferably, a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose.
- the present invention is directed to a cosmetic or medical method for treating a condition, disease, and/or lesion of the skin associated with regulation of pigmentation.
- the method includes applying a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose onto the skin, and the condition, disease, and/or lesion may be locally advanced due to an increase in synthesis of a melanin pigment, and may be at least one selected from the group consisting of chloasma, freckles, lentigo, nevi, pigmentation caused by use of drugs, post-inflammatory pigmentation, and hyperpigmentation occurring on dermatitis.
- the application frequency of the pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose may vary according to the demands of individual subjects.
- the application frequency is proposed to be ten times a month to a day, preferably four times a week to a day, more preferably three times a week to a day, and the most preferably one or twice a day.
- the present invention is directed to use of the 3,6-anhydro-L-galactose for preparing a pharmaceutical or cosmetic composition for treating, caring, and/or dressing the skin, preferably the skin of a face, a neck, a neckline, a hand, an armpit, a groin, an elbow, and/or a knee, and more preferably a local site of a face, a neck, and/or a hand.
- the present invention is directed to a pharmaceutical composition for preventing or treating an inflammatory disease, which includes 3,6-anhydro-L-galactose.
- the present invention is directed to a method of treating an inflammatory disease in an animal, which includes administering the composition for preventing or treating an inflammatory disease, which includes a pharmaceutically effective amount of 3,6-anhydro-L-galactose, to a subject.
- the present invention is directed to use of the 3,6-anhydro-L-galactose for preparing a pharmaceutical composition for preventing or treating an inflammatory disease.
- the 3,6-anhydro-L-galactose has an antioxidant activity to inhibit generation of nitrite (NO 2 ), and thus may be used in the pharmaceutical composition for preventing or treating an inflammatory disease since the 3,6-anhydro-L-galactose has the highest antioxidant activity, compared to D-form 3,6-anhydro galactose, and another disaccharide and monosaccharide, such as neoagarobiose and galactose, which constitutes a sea alga (see FIG. 8 ).
- the pharmaceutical composition used in the method of treating an inflammatory disease, and the method of administration are described above, the overlapping description of the pharmaceutical composition and the method of administration are omitted for clarity.
- the subject to which the pharmaceutical composition for preventing or treating an inflammatory disease may be administered may include all kinds of animals.
- the subject may be an animal except a human being, including a dog, a cat, a mouse, and the like.
- the effective amount of the active component in the pharmaceutical composition means an amount required to treat a disease. Therefore, the effective amount of the active component may be adjusted according to various factors including the kind of a disease, the severity of a disease, the kinds and contents of the active component and other components included in a composition, the kind of a formulation, the age, body weight, general physical condition, gender, and diet of a patient, the time and route of administration, the secretion rate of the composition, the duration of treatment, and drugs used together.
- treating means relieving symptoms, temporally or permanently removing the causes of the symptoms, or alleviating the onset and the progress of, or preventing the illness, disorder, or disease, but the present invention is not limited thereto.
- Agarose that is a representative polysaccharide constituting a sea alga was hydrolyzed with acetic acid. 5% (w/v) of agarose was reacted with 3M acetic acid at 80° C. for 70 minutes and dried to remove acetic acid. Also, acetic acid which remained after drying through a washing procedure using ethanol, and over-degradation products that were able to be produced upon hydrolysis were removed to produce an agarooligosaccharide in the form of a pure powder ( FIG. 2 ).
- Example 1 To degrade the acid hydrolysate produced in Example 1 into monosaccharides, D-galactose and 3,6-anhydro-L-galactose, the acid hydrolysate was reacted with an exo-type disaccharide-producing enzyme, Aga50D, (see Korean Patent Publication No. 2010-0040438) to produce neoagarobiose as a reaction product.
- Aga50D an exo-type disaccharide-producing enzyme
- the Aga50D reaction product was reacted with an sdNABH enzyme (see Korean Patent Publication No. 2010-0108241) in order to produce the monosaccharides, D-galactose and 3,6-anhydro-L-galactose, from the neoagarobiose.
- the enzymatic reaction conditions were as follows: 5% (w/v) of agarooligosaccharide was dissolved in 100 mL of a 50 mM Tris-HCl buffer solution (pH 7.4), and reacted at 30° C. and 150 rpm for 3 days.
- the amounts of the enzymes used upon the enzymatic reaction were 10 mg and 2.5 mg for Aga50D and sdNABH, respectively ( FIG. 2 ).
- agarooligosaccharide was produced from 100 g of agarose through chemical hydrolysis in Examples 1 to 3, and 37.55 g of neoagarobiose and 15.21 g of 3,6-anhydro-L-galactose were produced using the Aga50D and sdNABH enzymes, respectively. Also, 3.98 g of the pure 3,6-anhydro-L-galactose was purified through two chromatographies.
- the high-purity 3,6-anhydro-L-galactose produced in Example 3 was quantified through GC/MS analysis.
- a derivatization procedure for GC/MS analysis was as follows. The purified sample was dried in a speed-vac, added to 50 ⁇ l of 2% (w/v)O-methylhydroxylamine hydrochloride in pyridine, and then reacted at 75° C. for 30 minutes. Then, 80 ⁇ l of N-methyl-N-(trimethylsilyl)trifluoroacetamide was added, and reacted at 40° C. and 150 rpm for 30 minutes.
- the equipment conditions for GC/MS analysis were as follows. A column used for analysis was a DB5-MS capillary column.
- the sample was maintained at a temperature of 100° C. for 3.5 minutes, heated to 160° C., and maintained for 20 minutes. Thereafter, the sample was heated to 200° C., maintained for 15 minutes, finally heated to 280° C., and maintained for 5 minutes. 1 ⁇ l of the sample was analyzed at a split ratio of 9.6 ( FIG. 4 ).
- the melanoma cells B 16F10 were incubated. Before treatment with ⁇ -melanocyte-stimulating hormone that was a hormone promoting the melanin production, the melanoma cells were treated with each of arbutin most widely used as a whitening agent, saccharides (neoagarobiose, D-galactose, and 3,6-anhydro-D-galactose) constituting a red alga, and 3,6-anhydro-L-galactose at concentration of 1, 10, and 100 ⁇ g/mL, and the resulting reaction mixture was reacted with the ⁇ -melanocyte-stimulating hormone. After the melanoma cells were incubated together for 4 days, the optical densities of the melanoma cells were measured at 475 nm to determine the content of melanin.
- the concentration of nitrite (NO 2 ) in an RAW264.7 cell culture broth was measured by a method using a Griess reaction.
- the RAW264.7 cells were treated with a lipopolysaccharide at a concentration of 2 ⁇ g/mL, and simultaneously treated with each of neoagarobiose, galactose, 3,6-anhydro-D-galactose, and 3,6-anhydro-L-galactose at concentrations of 50, 100, and 200 ⁇ g/mL. Thereafter, the RAW264.7 cells were treated together to determine the antioxidant activities. After the RAW264.7 cells were incubated together for 24 hours, the optical densities of the RAW264.7 cells were measured at 540 nm to determine the antioxidant activities.
- Melanin is a natural pigment found to give colors to the skin and hair.
- the known main function of melanin is to protect the skin from DNA damage caused by irradiation of absorbed and scattered ultraviolet rays.
- the formation or abnormal distribution of excessive melanin may cause irregular skin hyperpigmentations such as chloasma, freckles, senile lentigos, and the like.
- ⁇ -MSH ⁇ -melanocyte-stimulating hormone
- ACTH ⁇ -melanocyte-stimulating hormone
- M1R melanocortin 1 receptor
- TRPs tyrosinase-related proteins
- TRP-1 is structurally associated with tyrosinase, has an amino acid homology of approximately 40%, and is present in the melanosomes such as tyrosinase.
- the previous studies reported that the mutations of TRP-1 resulted in pale skin or hair color, which was observed in a certain type of oculocutaneous albinism. Also, it was proposed that TRP-1 played a role in melanin biosynthesis since the inhibition of TRP-1 expression was associated with the hypopigmentation.
- HEMs human epidermal melanocytes
- Cascade Biologics (Oregon, USA)
- the cells were cultured at a temperature of 37° C. under a moisturizing environment containing 5% CO 2 .
- the culture medium for HEMs was Medium 254 (Cascade Biologics (Oregon, USA)) supplemented with HMGS.
- HEMs (1 ⁇ 10 5 ) were cultured in a 6-cm dish for 24 hours. Before the HEMs were exposed to 100 nM ⁇ -MSH (Sigma-Aldrich, St. Louis, Mo., USA) for several days, the cells were treated with 3,6-anhydro-L-galactose (L-AHG) at concentrations of 0, 25, 50, and 100 ⁇ g/mL for an hour.
- L-AHG 3,6-anhydro-L-galactose
- the cells were lysed in a lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ⁇ -glycerophosphate, 1 mM Na 3 VO 4 , 1 g/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail tablet].
- concentration of the proteins was measured according to the manufacturer's manual using a dye-conjugated protein assay kit (Bio-Rad Laboratories Inc.
- the membrane was incubated with a secondary antibody (a goat anti-rabbit IgG HRP-conjugated secondary antibody), and the antibody-bound proteins were detected using a chemifluorescence detection kit (Amersham Pharmacia Biotech, Piscataway, N.J.).
- a secondary antibody a goat anti-rabbit IgG HRP-conjugated secondary antibody
- the antibody-bound proteins were detected using a chemifluorescence detection kit (Amersham Pharmacia Biotech, Piscataway, N.J.).
- a secondary antibody a goat anti-rabbit IgG HRP-conjugated secondary antibody
- L-AHG was a novel hypopigmenting agent inhibiting the expression of tyrosinase and TRP-1.
- Hyaluronan is a glycosaminoglycan composed of D-glucuronic acid and N-acetyl-D-glucosamine. Due to its capability to store a large amount of water, HA functions to play an important role in regulating the water balance and osmotic pressure. HA is synthesized by HASs 1, 2, and 3 in a cell membrane. In particular, HAS2 is found in normal human tissues. The previous studies showed that the genetic defect of HAS2 induced the fatality in the prenatal period in a mouse model, and the HAS2 gene was expressed in the epidermis and the derma of an adult human skin to a decreased level.
- HAS2 expression could be a good strategy for maintaining the homeostasis in the skin.
- a western blot assay was performed.
- the cells used for this purpose were HaCaT cells, and incubated at 37° C. under a 5% CO 2 atmosphere in a Dulbecco's modified Eagle's medium (DMEM, GIBCO Invitrogen, Auckland, NZ) supplemented with 10% FBS and penicillin/streptomycin.
- DMEM Dulbecco's modified Eagle's medium
- the cells (1 ⁇ 10 5 ) were incubated for 24 hours in a 6-cm dish, and fasted in a serum-free medium for another 24 hours to get rid of an effect of FBS on activation of kinases. Thereafter, the cells were treated with 3,6-anhydro-L-galactose (L-AHG) at a predetermined concentration for a predetermined period of time.
- L-AHG 3,6-anhydro-L-galactose
- the cells were lysed in a lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ⁇ -glycerophosphate, 1 mM Na 3 VO 4 , 1 g/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail tablet].
- concentration of the proteins was measured according to the manufacturer's manual using a dye-conjugated protein assay kit (Bio-Rad Laboratories Inc).
- HAS2 expression was regulated by various inflammatory signal transduction pathways such as MAPKs and AKT. Therefore, the effects of L-AHG in the various inflammatory signal transduction pathways were measured.
- FIG. 13A it was revealed that 100 ⁇ g/mL of L-AHG significantly increased the phosphorylation of ERK 3 hours after the treatment.
- the cells were treated with L-AHG at concentrations of 25, 50, and 100 ⁇ g/mL. Similar to the HAS2 expression induced by L-AHG ( FIG. 13B ), it was revealed that the phosphorylation of ERK increased in an L-AHG concentration-dependent manner.
- FIG. 14A it was revealed that 100 ⁇ g/mL of L-AHG significantly increased the phosphorylation of AKT 3 hours after the treatment.
- the cells were treated with L-AHG at concentrations of 25, 50, and 100 ⁇ g/mL. And, it was revealed that L-AHG increased the phosphorylation of AKT in a concentration-dependent manner ( FIG. 14B ).
- a monosaccharide, 3,6-anhydro-L-galactose can be produced with a high yield by preparing an oligosaccharide under a mild chemical treatment condition in which an over-degradation effect according to chemical treatment is minimized and subjecting the oligosaccharide to enzymatic treatment.
- the physiological activities of 3,6-anhydro-L-galactose such as whitening, moisturizing, antioxidant, and anti-inflammatory activities, are first examined, resulting in use in various fields including foods, cosmetics, medicine, and the like. Therefore, the 3,6-anhydro-L-galactose considered to be a by-product or a fermentation inhibitor upon production of red alga-derived bioenergy can be applied to production of higher value-added materials in the field of bioenergy.
- 3,6-anhydro-L-galactose can be used as a whitening agent, a moisturizing agent, an antioxidant, a hypopigmenting agent, or an anti-inflammatory agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof.
Description
- 1. Field of the Invention
- The present invention relates to 3,6-anhydro-L-galactose prepared through chemical and enzymatic methods and industrial use thereof using physiological efficacy.
- 2. Discussion of Related Art
- Agar (or agarose) which is a main polysaccharide constituting a red alga is a polymer in which two monosaccharides, 3,6-anhydro-L-galactose and D-galactose, are alternately bound via α-1,3 linkage and β-1,4 linkage. It has been widely known in that an agarooligosaccharide produced by non-specifically hydrolyzing agarose using a chemical catalyst such as hydrochloric acid, sulfuric acid, and acetic acid exhibits excellent physiological activities such as antioxidant, anti-inflammatory, anti-cancer, whitening, and anti-allergic activities. Due to a variety of such physiological activities, agarooligosaccharides and neoagarobiose that are disaccharides have been widely used as functional materials in the fields of food and beauty industries.
- As one of monosaccharides constituting the agarooligosaccharides, 3,6-anhydro-L-galactose has problems in that it is produced as a monosaccharide with a very low yield through conventional chemical treatments, and is easily degraded to excessive extents since it has an unstable reducing end and is easily converted into hydroxymethylfurfural in the presence of a high-concentration strong acid under high-temperature reaction conditions (Jol et al (1999) Anal Biochem. 268, 213-222, Kim et al (2010) Bull Korean Soc. 31(2) 511-514). Also, although the hydrolysis using chemical treatment has an advantage in that it is readily applicable for the purpose of commercialization due to low production cost and simple treatment conditions, it has a problem in that a desired product is produced with a very low yield when specific linkages are broken to obtain the product since the chemical treatment non-specifically breaks the linkages (Chen et al (2005) Food Technol Biotechnol. 43(1) 29-36). Further, enzymes specifically breaking linkages in 3,6-anhydro-L-galactose to produce monosaccharides have been reported in recent years, but studies remain to be done to separate, purify, and quantify only 3,6-anhydro-L-galactose from a reaction product.
- Therefore, the present invention is directed to a method for preparing 3,6-anhydro-L-galactose with a high yield through enzymatic degradation while minimizing over-degradation effects caused by chemical treatment.
- Also, the present invention is directed to industrial use thereof to investigate the physiological activities of 3,6-anhydro-L-galactose.
- According to an aspect of the present invention, there is provided a method for preparing 3,6-anhydro-L-galactose, which includes preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours, and allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
- In this case, the agarose-degrading enzyme may be an enzyme that breaks a β-1,4-glycosidic linkage between D-galactose and 3,6-anhydro-L-galactose of agarose. More specifically, the agarose-degrading enzyme may be represented by an amino acid sequence set forth in SEQ ID NO: 1.
- The neoagarobiose hydrolase may be represented by an amino acid sequence set forth in SEQ ID NO: 3.
- According to one exemplary embodiment, the agarose-degrading enzyme and the neoagarobiose hydrolase may be derived from Saccharophagus degradans (S. degradans) 2-40.
- The method for preparing 3,6-anhydro-L-galactose according to one exemplary embodiment may further include separating and purifying the 3,6-anhydro-L-galactose by sequentially performing adsorption chromatography and gel-permeation chromatography on the 3,6-anhydro-L-galactose.
- According to another aspect of the present invention, there is provided a cosmetic composition for skin whitening or moisturizing including 3,6-anhydro-L-galactose.
- According to still another aspect of the present invention, there is provided cosmetic use of 3,6-anhydro-L-galactose for skin whitening or moisturizing.
- According to still another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a skin pigmentation disease including 3,6-anhydro-L-galactose.
- According to still another aspect of the present invention, there is provided use of the 3,6-anhydro-L-galactose for preparing the pharmaceutical composition for preventing or treating a skin pigmentation disease.
- According to still another aspect of the present invention, there is provided a cosmetic or medical method for whitening or moisturizing a skin of a mammal, preferably, a human, which requires skin whitening or moisturizing. Here, the cosmetic or medical method includes administering an effective amount of 3,6-anhydro-L-galactose, preferably, a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose.
- According to still another aspect of the present invention, there is provided a cosmetic or medical method for treating a condition, disease, and/or lesion of the skin associated with regulation of pigmentation. Here, the method includes applying a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose onto the skin, and the condition, disease, and/or lesion may be locally advanced due to an increase in synthesis of a melanin pigment, and may be at least one selected from the group consisting of chloasma, freckles, lentigo, nevi, pigmentation caused by use of drugs, post-inflammatory pigmentation, and hyperpigmentation occurring on dermatitis.
- According to still another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating an inflammatory disease, which includes 3,6-anhydro-L-galactose.
- According to still another aspect of the present invention, there is provided a method for treating an inflammatory disease in an animal. Here, the method includes administering the composition for preventing or treating an inflammatory disease, which includes a pharmaceutically effective amount of 3,6-anhydro-L-galactose, to a subject.
- According to yet another aspect of the present invention, there is provided use of 3,6-anhydro-L-galactose to prepare a pharmaceutical composition for preventing or treating an inflammatory disease.
-
FIG. 1 is a diagram illustrating a procedure of preparing 3,6-anhydro-L-galactose from agarose according to one exemplary embodiment of the present invention. InFIG. 1 , DP represents a degree of polymerization of a polysaccharide. -
FIG. 2 shows the thin-layer chromatography (TLC) results obtained in a procedure of preparing and purifying 3,6-anhydro-L-galactose from agarose. In the processing step,Lane 1 represents agarose,Lane 2 represents an acetic acid hydrolysate,Lane 3 represents an Aga50D reaction product,Lane 4 represents a sdNABH reaction product, Lane 5 represents 3,6-anhydro-L-galactose separated by silica gel chromatography,Lane 6 represents 3,6-anhydro-L-galactose purified by biogel P2 chromatography, AHG in the Y axis represents 3,6-anhydro-galactose, and NAB represents neoagarobiose. -
FIG. 3 shows the results of silica gel chromatography-TLC which is the first step of purifying 3,6-anhydro-L-galactose. InFIG. 3 , AHG represents 3,6-anhydro-galactose. -
FIG. 4 shows GC/MS total ion chromatograms of (a) a D-form 3,6-anhydro-galactose standard material and (b) 3,6-anhydro-L-galactose purified according to one exemplary embodiment of the present invention. -
FIG. 5 shows the 1H NMR analysis results of 3,6-anhydro-L-galactose separated and purified according to one exemplary embodiment of the present invention. -
FIG. 6 shows the 2D-HSQC NMR analysis results of 3,6-anhydro-L-galactose separated and purified according to one exemplary embodiment of the present invention. -
FIG. 7 shows the whitening activities of 3,6-anhydro-L-galactose, neoagarobiose, D-galactose, and 3,6-anhydro-D-galactose. InFIG. 7 , α-MSH represents an α-melanocyte-stimulating hormone, NAB represents neoagarobiose, and D-AHG and L-AHG represent D- and L-forms of 3,6-anhydro-galactose, respectively. -
FIG. 8 shows the antioxidant activities of 3,6-anhydro-L-galactose, neoagarobiose, D-galactose, and 3,6-anhydro-D-galactose. -
FIG. 9 shows effects of L-AHG on expression of tyrosinase induced by α-MSH in HEMs. Here,FIG. 9A shows the results of tyrosinase expression in the cells exposed to α-MSH after treatment according to concentrations of L-AHG, andFIG. 9B shows a graph obtained by plotting the results ofFIG. 9A as relative intensity of tyrosinase to β-actin. -
FIG. 10 shows effects of L-AHG on expression of TRP-1 induced by α-MSH in HEMs. Here,FIG. 10A shows the results of TRP-1 expression in the cells exposed to α-MSH after treatment according to concentrations of L-AHG, andFIG. 10B shows a graph obtained by plotting the results ofFIG. 10A as relative intensity of TRP-1 to β-actin. -
FIG. 11 shows effects of L-AHG on in vitro tyrosinase activities. -
FIG. 12 shows effects of L-AHG on expression of HAS2 in human corneous cells. Here,FIG. 12A shows an expression level of HAS2 after treatment with 100 μg/mL of L-AHG according to the elapse of time, andFIG. 12B shows an expression level of HAS2 after treatment according to concentrations of L-AHG -
FIG. 13 shows effects of L-AHG on phosphorylation of ERK in human corneous cells. Here,FIG. 13A shows the ERK phosphorylation results after treatment with 100 μg/mL of L-AHG according to the elapse of time, andFIG. 13B shows the ERK phosphorylation results after treatment according to concentrations of L-AHG -
FIG. 14 shows effects of L-AHG on phosphorylation of AKT in human corneous cells. Here,FIG. 14A shows the AKT phosphorylation results after treatment with 100 μg/mL of L-AHG according to the elapse of time, andFIG. 14B shows the AKT phosphorylation results after treatment according to concentrations of L-AHG - Hereinafter, exemplary embodiments of the present invention will be described in further detail.
- The present invention is directed to a method for preparing 3,6-anhydro-L-galactose, which includes preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours, and allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
- The method for preparing 3,6-anhydro-L-galactose according to one exemplary embodiment of the present invention is characterized in that agarose is hydrolyzed under mild conditions using a weak acid, an agarooligosaccharide separated from the acid hydrolysate is allowed to react with an exo-type agarose-degrading enzyme producing disaccharides to produce a neoagarobiose, and monosaccharides, galactose and 3,6-anhydro-L-galactose, are produced through additional reaction with a neoagarobiose hydrolase.
- The 3,6-anhydro-L-galactose may have a structure represented by the following Formula 1:
- The method of the present invention will be described in further detail with reference to the procedure of preparing 3,6-anhydro-L-galactose as shown in
FIG. 1 . - The first step is to prepare an agarooligosaccharide by treating agarose with a weak acid.
- The weak acid may be at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid, which may be used alone or in combination.
- The weak acid may be used at a concentration of 0.5 to 60% (w/v) in consideration of the unit production cost of and separation of salts produced after neutralization of weak acid. More specifically, the weak acid may be used at a concentration of 20 to 40% (w/v).
- The reaction of the weak acid with the agarose may be performed at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours. Within these ranges, formation of over-degradation products of agarose by the weak acid may be minimized.
- The reaction product obtained after the reaction is an agarooligosaccharide which may be washed to remove the over-degradation product with the residual weak acid, and dried so that the agarooligosaccharide can be obtained in a powdery form.
- As the washing solvent, a lower alcohol having 1 to 6 carbon atoms may be used, but the present invention is not limited thereto.
- The second step is to prepare 3,6-anhydro-L-galactose by enzymatic degradation of the agarooligosaccharide. Here, the enzymatic degradation is performed by producing a disaccharide, neoagarobiose, by treating the agarooligosaccharide with an exo-type agarose-degrading enzyme and degrading the neoagarobiose into D-galactose and 3,6-anhydro-L-galactose by treating the neoagarobiose with a neoagarobiose hydrolase.
- The enzymatic reaction may be performed at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
- The enzymatic reaction will be described in further detail, as follows.
- First, an enzyme breaking a β-1,4-glycosidic linkage between D-galactose and 3,6-anhydro-L-galactose of agarose (hereinafter referred to as ‘Aga50D’) may be used as the agarose-degrading enzyme degrading the agarooligosaccharide to produce the disaccharide, neoagarobiose.
- The agarose-degrading enzyme may include an amino acid sequence set forth in SEQ ID NO: 1, and amino acid sequences having sequence identities of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with respect to the amino acid sequence.
- In the present invention, a polypeptide having a sequence identity of certain percentage (for example, 80%, 85%, 90%, 95%, or 99%) with respect to another sequence means that two sequences has the same amino acid residues at any percentage upon sequence comparison when the sequences are aligned to each other. The alignment and percentage homology or identity may be determined using any proper software program known in the related art, for example, those described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al., (eds) 1987 Supplement 30 section 7.7.18). A preferred program includes GCG Pileup programs, for example FASTA (Pearson, et al., 1988 Proc. Natl. Acad. Sci. USA 85: 2444-2448), and BLAST (BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med. (NCIB NLM NIH), Bethesda, Md., and Altschul et al., 1997 NAR25: 3389-3402). Another preferred alignment program is ALIGN Plus (Scientific and Educational Software, PA), which preferably uses basic parameters. Still another preferred sequence software program which may be used herein is a TFASTA Data Searching program available for Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison Wis.).
- In this specification, the terms “protein” and “polypeptide” may be used interchangeably. In this specification, one-letter or three-letter codes for amino acid residues are typically used herein.
- The enzyme may be derived from S. degradans 2-40, but the present invention is not limited thereto.
- The enzyme may be transcribed and translated through a coding gene, that is, a DNA fragment which is associated with production of a polypeptide including regions upstream and downstream of a coding region of the enzyme and an intervening sequence between individual coding fragments. For example, the enzyme may have a sequence set forth in SEQ ID NO: 2, but the present invention is not limited thereto.
- The agarose-degrading enzyme according to one exemplary embodiment of the present invention may be separated and purified from a supernatant of the S. degradans culture broth, and may be produced and separated in the strains other than S. degradans using a genetic recombination technique or an artificial chemical synthesis method.
- When the recombination technique is used, factors used to facilitate expression of typical recombinant proteins, for example, antibiotic-resistant genes, and reporter proteins or peptides usable for affinity column chromatography may be used herein. Such a technique falls within a category which can be easily carried out by those skilled in the art to which the present invention belongs. Also, a supernatant of the S. degradans culture broth may be used instead of the agarose-degrading enzyme according to one exemplary embodiment of the present invention, or a supernatant of a culture broth of an edible strain, for example, a transformed yeast strain obtained by transforming a yeast strain, may be used instead of the agarose-degrading enzyme.
- In the present invention, the term “recombination” used in connection with cells, nucleic acids, proteins, or vectors means that the cells, nucleic acids, proteins, or vectors are modified by introduction of heterogeneous nucleic acids or proteins or alteration of innate nucleic acids or proteins, or that the cells are derived from such modified cells. That is, the recombinant cells, for example, express genes which are not found in the cells in an original non-recombinant form, or express original genes which are expressed abnormally upon expression or not expressed at all.
- In this specification, the term “nucleic acid” encompasses all kinds of single- or double-stranded DNAs, RNAs, and chemical variants thereof. The terms “nucleic acid” and “polynucleotide” may be used interchangeably herein. Since the genetic codes are degenerated, one or more codons may be used to encode one certain amino acid, and the present invention covers polynucleotides encoding certain amino acid sequences.
- The term “introduction” used to insert a nucleic acid sequence into cells refers to “transfection,” “transformation,” or “transduction,” and encompasses reference to integration of a nucleic acid sequence into eucaryotic or procaryotic cells. In this case, the nucleic acid sequence is integrated into the genome (for example, a chromosome, a plasmid, a chromatophore, or mitochondrial DNA) of a cell, and converted into an autonomous replicon or expressed temporally.
- The reaction of the agarooligosaccharide with the agarose-degrading enzyme may be performed at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days. More specifically, such a reaction may be performed at a temperature of 25 to 35° C. and a rotary speed of 100 to 150 rpm for 1 to 4 days.
- When the agarooligosaccharide is in a powdery form, the agarooligosaccharide may be dissolved in a conventional buffer solution to be used, but the present invention is not limited thereto.
- Next, the neoagarobiose hydrolase that can degrade the neoagarobiose produced through the enzymatic reaction into D-galactose and 3,6-anhydro-L-galactose may be a protein having an amino acid sequence set forth in SEQ ID NO: 3 and a mutant protein having at least one substitution, deletion, translocation, and addition in the enzyme. Proteins having the neoagarobiose-hydrolytic activities are also included in a category of the enzymes according to one exemplary embodiment of the present invention, and, preferably, has an amino acid sequence having a sequence identity of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, and 99% or more with respect to the amino acid sequence set forth in SEQ ID NO: 3 (hereinafter referred to as ‘sdNABH’).
- The enzyme may be derived from S. degradans 2-40, but the present invention is not limited thereto.
- The enzyme may be transcribed and translated through a coding gene, that is, a DNA fragment which is associated with production of a polypeptide including regions upstream and downstream of a coding region of the enzyme and an intervening sequence between individual coding fragments. For example, the enzyme may have a sequence set forth in SEQ ID NO: 4, but the present invention is not limited thereto.
- The neoagarobiose hydrolase may be separated and purified from a supernatant of the S. degradans culture broth, and may be produced and separated in the strains other than S. degradans using a genetic recombination technique or an artificial chemical synthesis method.
- When the recombination technique is used, factors used to facilitate expression of typical recombinant proteins, for example, antibiotic-resistant genes, and reporter proteins or peptides usable for affinity column chromatography may be used herein. Such a technique falls within a category which can be easily carried out by those skilled in the art to which the present invention belongs. Also, a supernatant of the S. degradans culture broth may be used instead of the neoagarobiose hydrolase according to one exemplary embodiment of the present invention, or a supernatant of a culture broth of an edible strain, for example, a transformed yeast strain obtained by transforming a yeast strain, may be used instead of the neoagarobiose hydrolase.
- The reaction of the neoagarobiose with the neoagarobiose hydrolase may be performed at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days. More specifically, such a reaction may be performed at a temperature of 25 to 35° C. and a rotary speed of 100 to 150 rpm for 1 to 4 days.
- Also, the method for preparing 3,6-anhydro-L-galactose according to one exemplary embodiment of the present invention may further include separating and purifying only 3,6-anhydro-L-galactose from the degradation products of neoagarobiose.
- The 3,6-anhydro-L-galactose may be separated and purified with a high purity of approximately 96% by sequentially performing silica gel chromatography that is adsorption chromatography and biogel P2 chromatography that is gel-permeation chromatography.
- The purified product is subjected to 1H-NMR and 2D-heteronuclear single quantum coherence (HSQC) NMR analysis, and 1H ppm and 13C ppm of previously reported 3,6-anhydro-L-galactose may be compared to identify the structure of the purified product.
- In the preparation method according to one exemplary embodiment of the present invention, 76 g of the agarooligosaccharide may be produced from 100 g of agarose through chemical hydrolysis, and 37.55 g of the neoagarobiose and 15.21 g of the 3,6-anhydro-L-galactose may be produced using the Aga50D and sdNABH enzymes, respectively. Also, 3.98 g of pure 3,6-anhydro-L-galactose may be purified through a purification procedure using two kinds of chromatographies.
- The present invention is also directed to a cosmetic composition for skin whitening or moisturizing including 3,6-anhydro-L-galactose.
- Further, the present invention is directed to cosmetic use of 3,6-anhydro-L-galactose for skin whitening or moisturizing.
- The 3,6-anhydro-L-galactose has higher whitening activities than arbutin that has been most widely known as a conventional whitening material, and has an effect of inhibiting the expression of tyrosinase, TRP-1, and the like, which are associated with promoting synthesis of melanin, in a concentration-dependent manner.
- According to one exemplary embodiment of the present invention, an in vitro tyrosinase activity test shows that the 3,6-anhydro-L-galactose exhibits a whitening effect by inhibiting expression of the enzyme rather than inhibiting the tyrosinase activities.
- Also, the 3,6-anhydro-L-galactose has an effect of promoting the expression of a HAS2 protein that is a moisturizing marker associated with the synthesis of hyaluronic acid.
- According to one exemplary embodiment of the present invention, the expression of the HAS2 protein may be regulated by various inflammatory signal transduction pathways such as ERK, and AKT. Here, the 3,6-anhydro-L-galactose may increase phosphorylation of ERK and AKT, and the highly phosphorylated ERK and AKT may increase the expression of the HAS2 protein.
- The 3,6-anhydro-L-galactose may be used without limitation as long as it may be synthesized, or may be prepared using the method for preparing 3,6-anhydro-L-galactose according to one exemplary embodiment of the present invention.
- Based on an effective amount, a cosmetic preparation or cosmetics including the 3,6-anhydro-L-galactose itself or a mixture obtained by mixing a cosmetologically acceptable carrier with the 3,6-anhydro-L-galactose may be provided. In this case, the cosmetic preparation or cosmetics may be prepared into typical emulsified and solubilized formulations. In the emulsified formulation, the cosmetics may include a lotion, a cream, an essence, and the like, and, in the solubilized formulation, the cosmetics may be a toner. Proper formulations of the cosmetics may, for example, be provided in the form of a solution, a gel, a solid or pasty anhydrous product, an emulsion obtained by dispersing an oily phase in a water phase, a suspension, a microemulsion, a microcapsule, a microgranulocyte, or an ionic (liposomal) or non-ionic vesicle dispersing agent, or may also be provided in the form of a cream, a toner, a lotion, a powder, an ointment, a spray, or a conceal stick.
- Also, the formulations of the cosmetics may be prepared in the form of a foam or an aerosol composition further including a compressed propellant.
- In this case, the method of preparing cosmetics in the above-described form, and the carrier are apparent to those skilled in the art, and thus the specific description of the method of preparing cosmetics is omitted for clarity.
- In addition to the 3,6-anhydro-L-galactose according to one exemplary embodiment of the present invention, the cosmetics may include supplemental agents typically used in the field of cosmetology, such as a fat material, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizing agent, a foaming agent, an aromatic, a surfactant, water, an ionic or non-ionic emulsifying agent, a filler, a metal ion sequestering and chelating agent, a preservative, a vitamin, a blocking agent, a moisturizing agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic activating agent, a lipid vesicle, or any other components typically used in cosmetics.
- When the 3,6-anhydro-L-galactose is used for foods or as a food additive, the 3,6-anhydro-L-galactose itself may be added, or may be used in connection with other foods or food components. In this case, the 3,6-anhydro-L-galactose may be properly used according to conventional methods. The amount of the mixed active component may be determined according to a purpose of use (prophylaxis, health, or therapeutic treatment). In general, the composition according to one exemplary embodiment of the present invention may be added at a content of 15 wt % or less, preferably 10 wt % or less, based on the total amount of the active component, upon preparation of foods. However, when the 3,6-anhydro-L-galactose is taken in for a long period of time for the purpose of health and hygiene or the purpose of regulation of health, the amount of the mixed active component may be lower than or equal to the above-described content. When the mixed active component has no problems regarding the safety, the active component may also be used within this content range or less.
- The present invention is also directed to a pharmaceutical composition for preventing or treating a skin pigmentation disease, which includes 3,6-anhydro-L-galactose.
- Also, the present invention is directed to use of the 3,6-anhydro-L-galactose for preparing the pharmaceutical composition for preventing or treating a skin pigmentation disease.
- The pharmaceutical composition according to one exemplary embodiment of the present invention may further include a suitable carrier, excipient, and diluent which are typically used to prepare pharmaceutical compositions.
- The pharmaceutical composition according to one exemplary embodiment of the present invention may be formulated in the form of external preparations such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, syrup, and an aerosol, and in the form of a sterile injectable solution according to conventional methods. Preferably, the pharmaceutical composition may be used in the form of a cream, a gel, a patch, a spraying agent, an ointment, a plaster, a lotion, a liniment, a paste, or a cataplasma.
- The carrier, excipient, and diluent that may be included in the pharmaceutical composition according to one exemplary embodiment of the present invention may include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.
- When formulated, the pharmaceutical composition may be prepared using a diluent or excipient widely used in the related art, such as a filler, an extending agent, a binding agent, a wetting agent, a disintegrating agent, a surfactant, and the like.
- A solid preparation for oral administration may include a tablet, a pill, a powder, a granule, a capsule, and the like. Such a solid preparation may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, or gelatin, with the above-described compound. In addition to the simple excipients, lubricants such as magnesium stearate and talc may also be used. A liquid preparation for oral administration may include a suspension, a liquid for internal use, an emulsion, syrup, and the like. In addition to the widely used simple diluents such as water and liquid paraffin, the liquid preparation may include various excipients, for example, a wetting agent, a sweetening agent, an aromatic, a preservative, and the like. A preparation for parenteral administration may include a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, a suppository, and the like. A vegetable oil such as propylene glycol, polyethylene glycol, or olive oil, or an injectable ester such as ethyl oleate may be used as the non-aqueous solvent and the suspension. Witepsol, Macrogol, Tween 61, cocoa butter, laurin butter, glycerogelatin, and the like may be used as base of the suppository.
- The pharmaceutical composition according to one exemplary embodiment of the present invention may be a formulation for external use in the skin which can be applied to the skin. In this case, the pharmaceutical composition may be prepared in the form of a liquid for external use, such as a cream, a gel, a patch, a spraying agent, an ointment, a plaster, a lotion, a liniment, a paste, or a cataplasma, but the present invention is not limited thereto.
- A desirable dose of the pharmaceutical composition according to one exemplary embodiment of the present invention may vary according to the conditions and body weight of a patient, the severity of a disease, the type of a drug, and the route and duration of administration, but may be properly chosen by those skilled in the related art. However, the composition according to one exemplary embodiment of the present invention may be administered daily at a dose of 0.0001 to 100 mg/kg, preferably 0.001 to 10 mg/kg, in order to show a desirable medicinal effect. The liquid for external use may be administered once or several times a day. The dosage is not intended to limit the scope of the present invention at any aspects.
- Also, the present invention is directed to a cosmetic or medical method for whitening or moisturizing a skin of a mammal, preferably, a human, which requires skin whitening or moisturizing. Here, the cosmetic or medical method includes administering an effective amount of 3,6-anhydro-L-galactose, preferably, a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose.
- Likewise, the present invention is directed to a cosmetic or medical method for treating a condition, disease, and/or lesion of the skin associated with regulation of pigmentation. Here, the method includes applying a pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose onto the skin, and the condition, disease, and/or lesion may be locally advanced due to an increase in synthesis of a melanin pigment, and may be at least one selected from the group consisting of chloasma, freckles, lentigo, nevi, pigmentation caused by use of drugs, post-inflammatory pigmentation, and hyperpigmentation occurring on dermatitis.
- The application frequency of the pharmaceutical or cosmetic composition including 3,6-anhydro-L-galactose may vary according to the demands of individual subjects. For example, the application frequency is proposed to be ten times a month to a day, preferably four times a week to a day, more preferably three times a week to a day, and the most preferably one or twice a day.
- Also, the present invention is directed to use of the 3,6-anhydro-L-galactose for preparing a pharmaceutical or cosmetic composition for treating, caring, and/or dressing the skin, preferably the skin of a face, a neck, a neckline, a hand, an armpit, a groin, an elbow, and/or a knee, and more preferably a local site of a face, a neck, and/or a hand.
- Further, the present invention is directed to a pharmaceutical composition for preventing or treating an inflammatory disease, which includes 3,6-anhydro-L-galactose.
- Also, the present invention is directed to a method of treating an inflammatory disease in an animal, which includes administering the composition for preventing or treating an inflammatory disease, which includes a pharmaceutically effective amount of 3,6-anhydro-L-galactose, to a subject.
- Furthermore, the present invention is directed to use of the 3,6-anhydro-L-galactose for preparing a pharmaceutical composition for preventing or treating an inflammatory disease.
- The 3,6-anhydro-L-galactose has an antioxidant activity to inhibit generation of nitrite (NO2), and thus may be used in the pharmaceutical composition for preventing or treating an inflammatory disease since the 3,6-anhydro-L-galactose has the highest antioxidant activity, compared to D-
form 3,6-anhydro galactose, and another disaccharide and monosaccharide, such as neoagarobiose and galactose, which constitutes a sea alga (seeFIG. 8 ). - Since the pharmaceutical composition used in the method of treating an inflammatory disease, and the method of administration are described above, the overlapping description of the pharmaceutical composition and the method of administration are omitted for clarity. Meanwhile, the subject to which the pharmaceutical composition for preventing or treating an inflammatory disease may be administered may include all kinds of animals. For example, the subject may be an animal except a human being, including a dog, a cat, a mouse, and the like.
- The effective amount of the active component in the pharmaceutical composition means an amount required to treat a disease. Therefore, the effective amount of the active component may be adjusted according to various factors including the kind of a disease, the severity of a disease, the kinds and contents of the active component and other components included in a composition, the kind of a formulation, the age, body weight, general physical condition, gender, and diet of a patient, the time and route of administration, the secretion rate of the composition, the duration of treatment, and drugs used together.
- Also, the term “treating” or “treatment” means relieving symptoms, temporally or permanently removing the causes of the symptoms, or alleviating the onset and the progress of, or preventing the illness, disorder, or disease, but the present invention is not limited thereto.
- Hereinafter, the present invention will be described in further detail with reference to the following preferred Examples. However, it should be understood that the following Examples are given by way of illustration of the present invention only, and are not intended to limit the scope of the present invention.
- Agarose that is a representative polysaccharide constituting a sea alga was hydrolyzed with acetic acid. 5% (w/v) of agarose was reacted with 3M acetic acid at 80° C. for 70 minutes and dried to remove acetic acid. Also, acetic acid which remained after drying through a washing procedure using ethanol, and over-degradation products that were able to be produced upon hydrolysis were removed to produce an agarooligosaccharide in the form of a pure powder (
FIG. 2 ). - To degrade the acid hydrolysate produced in Example 1 into monosaccharides, D-galactose and 3,6-anhydro-L-galactose, the acid hydrolysate was reacted with an exo-type disaccharide-producing enzyme, Aga50D, (see Korean Patent Publication No. 2010-0040438) to produce neoagarobiose as a reaction product.
- When the reaction with Aga50D was completed, the Aga50D reaction product was reacted with an sdNABH enzyme (see Korean Patent Publication No. 2010-0108241) in order to produce the monosaccharides, D-galactose and 3,6-anhydro-L-galactose, from the neoagarobiose. The enzymatic reaction conditions were as follows: 5% (w/v) of agarooligosaccharide was dissolved in 100 mL of a 50 mM Tris-HCl buffer solution (pH 7.4), and reacted at 30° C. and 150 rpm for 3 days. The amounts of the enzymes used upon the enzymatic reaction were 10 mg and 2.5 mg for Aga50D and sdNABH, respectively (
FIG. 2 ). - Chromatography was performed to separate and purify only 3,6-anhydro-L-galactose from the reaction products produced in Examples 1 and 2. The reaction products were adsorbed onto celite to form a sample in the form of powder, and subjected to silica gel chromatography that was adsorption chromatography. A solvent obtained by mixing chloroform, methanol, and water at a ratio of 78:20:2 (v/v/v) was used as a mobile phase, and the total volume of the solvent as the mobile phase was 3 L. The volume of one fraction was 20 mL, and the sample composed of a total of 150 fractions was analyzed through TLC. Among these, the fractions containing 3,6-anhydro-L-galactose were collected. Since the biogel P2 chromatography to be further performed separated materials according to the molecular weights, the fractions containing D-galactose having a molecular weight similar to 3,6-anhydro-L-galactose among the fractions containing 3,6-anhydro-L-galactose were excluded (
FIG. 3 ). - Only 3,6-anhydro-L-galactose was able to be purified from the disaccharides and the agarooligosaccharide having a low degree of polymerization with high purity through biogel P2 chromatography. The mobile phase used herein was water, and the volume of one fraction was 2 mL. Among the respective fractions, only the fractions showing spots of 3,6-anhydro-L-galactose on TLC were collected to obtain high-
purity 3,6-anhydro-L-galactose (FIG. 2 ). - As shown in
FIG. 2 , 76 g of the agarooligosaccharide was produced from 100 g of agarose through chemical hydrolysis in Examples 1 to 3, and 37.55 g of neoagarobiose and 15.21 g of 3,6-anhydro-L-galactose were produced using the Aga50D and sdNABH enzymes, respectively. Also, 3.98 g of the pure 3,6-anhydro-L-galactose was purified through two chromatographies. - Also as shown in
FIG. 3 , no saccharides were observed in fractions 0.25-067 of elution volume (L), the sugars other than 3,6-anhydro-L-galactose and galactose were observed in fractions 0.77-1.77 (a sample subjected to biogel P2 chromatography after the concentration), and galactose and other sugars were observed in fractions 1.87-2.67. - The high-
purity 3,6-anhydro-L-galactose produced in Example 3 was quantified through GC/MS analysis. A derivatization procedure for GC/MS analysis was as follows. The purified sample was dried in a speed-vac, added to 50 μl of 2% (w/v)O-methylhydroxylamine hydrochloride in pyridine, and then reacted at 75° C. for 30 minutes. Then, 80 μl of N-methyl-N-(trimethylsilyl)trifluoroacetamide was added, and reacted at 40° C. and 150 rpm for 30 minutes. The equipment conditions for GC/MS analysis were as follows. A column used for analysis was a DB5-MS capillary column. In the case of the GC column temperature conditions, first, the sample was maintained at a temperature of 100° C. for 3.5 minutes, heated to 160° C., and maintained for 20 minutes. Thereafter, the sample was heated to 200° C., maintained for 15 minutes, finally heated to 280° C., and maintained for 5 minutes. 1 μl of the sample was analyzed at a split ratio of 9.6 (FIG. 4 ). - NMR analyses were performed to identify the chemical structure of the high-
purity 3,6-anhydro-L-galactose produced in Examples 1 to 3. 2 mg of a 3,6-anhydro-L-galactose sample was dissolved in D2O, and 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid was added as the internal standard to calculate the chemical shift. It was confirmed that the chemical structure was identified by comparing the chemical shifts in 1H-NMR and 2D HSQC NMR to the resulting values of the previously reported documents (Sugano et al (1994) J Bacteriol. 176(22) 6812-6818, Miller et al (1982) Aust J Chem. 35(4) 853-856)(FIG. 5 and 6). - To determine the whitening activities of the high-
purity 3,6-anhydro-L-galactose produced in Examples 1 to 3, the melanoma cells, B 16F10, were incubated. Before treatment with α-melanocyte-stimulating hormone that was a hormone promoting the melanin production, the melanoma cells were treated with each of arbutin most widely used as a whitening agent, saccharides (neoagarobiose, D-galactose, and 3,6-anhydro-D-galactose) constituting a red alga, and 3,6-anhydro-L-galactose at concentration of 1, 10, and 100 μg/mL, and the resulting reaction mixture was reacted with the α-melanocyte-stimulating hormone. After the melanoma cells were incubated together for 4 days, the optical densities of the melanoma cells were measured at 475 nm to determine the content of melanin. - As a result, it was revealed that the 3,6-anhydro-L-galactose showed very excellent whitening activities, compared to the other treated groups, and, in fact, that the 3,6-anhydro-L-galactose showed higher whitening activities than arbutin which is known as a functional material showing whitening activities (
FIG. 7 ). - To determine the antioxidant activities of the high-
purity 3,6-anhydro-L-galactose produced in Examples 1 to 3, the concentration of nitrite (NO2) in an RAW264.7 cell culture broth was measured by a method using a Griess reaction. The RAW264.7 cells were treated with a lipopolysaccharide at a concentration of 2 μg/mL, and simultaneously treated with each of neoagarobiose, galactose, 3,6-anhydro-D-galactose, and 3,6-anhydro-L-galactose at concentrations of 50, 100, and 200 μg/mL. Thereafter, the RAW264.7 cells were treated together to determine the antioxidant activities. After the RAW264.7 cells were incubated together for 24 hours, the optical densities of the RAW264.7 cells were measured at 540 nm to determine the antioxidant activities. - As a result, it was revealed that the 3,6-anhydro-L-galactose showed very excellent antioxidant activities, compared to the other treated groups, and that the 3,6-anhydro-L-galactose showed higher antioxidant activities than the previously reported 3,6-anhydro-D-galactose (
FIG. 8 ). - Melanin is a natural pigment found to give colors to the skin and hair. The known main function of melanin is to protect the skin from DNA damage caused by irradiation of absorbed and scattered ultraviolet rays. However, the formation or abnormal distribution of excessive melanin may cause irregular skin hyperpigmentations such as chloasma, freckles, senile lentigos, and the like. The previous studies showed that the ultraviolet irradiation increases levels of an α-melanocyte-stimulating hormone (α-MSH) and ACTH, and a related receptor thereof, that is, a
melanocortin 1 receptor (MC1R) to promote the expression of melanin biosynthesis enzymes including tyrosinase, and tyrosinase-related proteins (TRPs). A copper-containing glycoprotein, tyrosinase, is a rate limiting enzyme which is important for synthesis of melanin in certain cell organs, that is, melanosomes produced only in melanocytes. Therefore, a decrease in tyrosinase expression was considered to be a good strategy for inhibiting the pigmentation of the skin. - Also, TRP-1 is structurally associated with tyrosinase, has an amino acid homology of approximately 40%, and is present in the melanosomes such as tyrosinase. The previous studies reported that the mutations of TRP-1 resulted in pale skin or hair color, which was observed in a certain type of oculocutaneous albinism. Also, it was proposed that TRP-1 played a role in melanin biosynthesis since the inhibition of TRP-1 expression was associated with the hypopigmentation.
- Therefore, effects of L-AHG on tyrosinase and TRP-1 expression induced by α-MSH were examined in order to evaluate whether L-AHG had the probability of showing the whitening activities on the skin. Properly pigmented human epidermal melanocytes (HEMs, Cascade Biologics (Oregon, USA)) derived from the neonatal epidermis were used as the cells for this purpose. The cells were cultured at a temperature of 37° C. under a moisturizing environment containing 5% CO2. The culture medium for HEMs was Medium 254 (Cascade Biologics (Oregon, USA)) supplemented with HMGS.
- HEMs (1×105) were cultured in a 6-cm dish for 24 hours. Before the HEMs were exposed to 100 nM α-MSH (Sigma-Aldrich, St. Louis, Mo., USA) for several days, the cells were treated with 3,6-anhydro-L-galactose (L-AHG) at concentrations of 0, 25, 50, and 100 μg/mL for an hour. Then, the cells were lysed in a lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 g/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail tablet]. The concentration of the proteins was measured according to the manufacturer's manual using a dye-conjugated protein assay kit (Bio-Rad Laboratories Inc. Hercules, Calif., USA). 10% SDS-PAGE was performed on the lysed proteins (20 to 40 μg), and the lysed proteins were transferred to a polyvinylidene fluoride (PVDF) membrane through electrophoresis (Millipore Corp., Bedford, Mass., USA). After blotting, the membrane was blocked with 5% skim milk (MB cell, Los Angeles, Calif., USA) for 2 hours, and incubated with a primary antibody (goat anti-mouse IgG-HRP) overnight at 4° C. Thereafter, the membrane was incubated with a secondary antibody (a goat anti-rabbit IgG HRP-conjugated secondary antibody), and the antibody-bound proteins were detected using a chemifluorescence detection kit (Amersham Pharmacia Biotech, Piscataway, N.J.). As the control, an expression level of β-actin was measured. The data represented the values obtained from the independent experiments performed in duplicate.
- The in vitro tyrosinase analyses were performed using a slight modification of the reported method (Ishihara Y et al., The journal of antibiotics (Tokyo) 1991; 44:25-32; An SM, Koh J S, Boo Y C, Phytotherapy Research 2010; 24:1175-1180). In brief, 250 μl of a 0.1M potassium phosphate buffer (pH 6.8) was put into a 24-well plate, and 25 μl of a mushroom-derived tyrosinase (2,000 units/mL), 25 μl of a sample, and 225 μl of distilled water were put into each well. The plate was incubated at 25° C. for 10 minutes, and 25 μl of 1 mM L-tyrosine used as a substrate was added to the wells. Then, the plate was incubated at 25° C. for 10 minutes, and the optical density of each well measured at 475 nm using a microplate reader (Sunrise-Basic Tecan, Austria). Each of the measured values was represented by a variation (%) with respect to the control. L-tyrosine was used as the substrate, and arbutin was used as the positive control. The results were represented by the relative tyrosinase activities to the non-treated control.
- As shown in
FIG. 9 , it was revealed that the tyrosinase expression induced by α-MSH significantly decreased in the HEMs when the HEMs were treated with 100 μg/mL of L-AHG, compared to the tyrosinase expression induced by α-MSH. - Also, it was confirmed that, similar to the decrease in the tyrosinase expression by L-AHG treatment (
FIG. 9A ), the TRP-1 expression in the HEMs decreased in an L-AHG concentration-dependent manner (FIG. 10 ). - Next, effects of L-AHG on the tyrosinase activities were examined using a cell-free assay system. Many reports disclosed that the mushroom-derived tyrosinase was primarily used as a model since it was able to be used in the form of a tablet. Arbutin that was a competitive inhibitor of L-tyrosine was used as the positive control, and inhibited the tyrosinase activities in the mushroom (
FIG. 11 ). The results were represented by the relative tyrosinase activities to the non-treated control. The data represented the average values±S.D. obtained from the independent experiments performed in triplicate, and the student's t-test was used for single statistical comparison. A significance value of p<0.05 was used as the standard to the statistical significance. An asterisk represents a significant difference (p<0.05) compared to the non-treated control. - As shown in
FIG. 11 , it was revealed that L-AHG did induce no significant decrease in the tyrosinase activities in the mushroom, and that arbutin induced a decrease in the tyrosinase activities to 40% at a concentration of 200 μM. - In sum, the results addressed that L-AHG was a novel hypopigmenting agent inhibiting the expression of tyrosinase and TRP-1.
- Hyaluronan (HA) is a glycosaminoglycan composed of D-glucuronic acid and N-acetyl-D-glucosamine. Due to its capability to store a large amount of water, HA functions to play an important role in regulating the water balance and osmotic pressure. HA is synthesized by
HASs - The cells (1×105) were incubated for 24 hours in a 6-cm dish, and fasted in a serum-free medium for another 24 hours to get rid of an effect of FBS on activation of kinases. Thereafter, the cells were treated with 3,6-anhydro-L-galactose (L-AHG) at a predetermined concentration for a predetermined period of time. Then, the cells were lysed in a lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 g/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail tablet]. The concentration of the proteins was measured according to the manufacturer's manual using a dye-conjugated protein assay kit (Bio-Rad Laboratories Inc). 10% SDS-PAGE was performed on the lysed proteins (20 to 40 μg), and the lysed proteins were transferred to a PVDF membrane through electrophoresis (Millipore Corp., Bedford, Mass., USA). After blotting, the membrane was blocked with 5% skim milk for 2 hours, and incubated with a primary antibody (goat anti-mouse IgG-HRP) overnight at 4° C. Thereafter, the membrane was incubated with a secondary antibody (a goat anti-rabbit IgG HRP-conjugated secondary antibody), and the antibody-bound proteins were detected using a chemifluorescence detection kit (Amersham Pharmacia Biotech, Piscataway, N.J.). The data represented the values obtained from the independent experiments performed in duplicate.
- As shown in
FIG. 12 , it was revealed that L-AHG increased the HAS2 expression at 3 hours after the treatment. Also, it was confirmed that L-AHG increased the HAS2 expression in a concentration-dependent manner. - It was reported that the HAS2 expression was regulated by various inflammatory signal transduction pathways such as MAPKs and AKT. Therefore, the effects of L-AHG in the various inflammatory signal transduction pathways were measured.
- As shown in
FIG. 13A , it was revealed that 100 μg/mL of L-AHG significantly increased the phosphorylation ofERK 3 hours after the treatment. To measure a concentration-dependent effect of L-AHG on the phosphorylation of ERK, the cells were treated with L-AHG at concentrations of 25, 50, and 100 μg/mL. Similar to the HAS2 expression induced by L-AHG (FIG. 13B ), it was revealed that the phosphorylation of ERK increased in an L-AHG concentration-dependent manner. - As shown in
FIG. 14A , it was revealed that 100 μg/mL of L-AHG significantly increased the phosphorylation ofAKT 3 hours after the treatment. To measure a concentration-dependent effect of L-AHG on the phosphorylation of AKT, the cells were treated with L-AHG at concentrations of 25, 50, and 100 μg/mL. And, it was revealed that L-AHG increased the phosphorylation of AKT in a concentration-dependent manner (FIG. 14B ). - In summary, the results addressed that the phosphorylation of ERK and AKT induced by L-AHG contributed to an increase in the HAS2 expression by L-AHG
- According to exemplary embodiments of the present invention, a monosaccharide, 3,6-anhydro-L-galactose, can be produced with a high yield by preparing an oligosaccharide under a mild chemical treatment condition in which an over-degradation effect according to chemical treatment is minimized and subjecting the oligosaccharide to enzymatic treatment.
- Also, according to the present invention, the physiological activities of 3,6-anhydro-L-galactose, such as whitening, moisturizing, antioxidant, and anti-inflammatory activities, are first examined, resulting in use in various fields including foods, cosmetics, medicine, and the like. Therefore, the 3,6-anhydro-L-galactose considered to be a by-product or a fermentation inhibitor upon production of red alga-derived bioenergy can be applied to production of higher value-added materials in the field of bioenergy.
- According to exemplary embodiments of the present invention, 3,6-anhydro-L-galactose can be used as a whitening agent, a moisturizing agent, an antioxidant, a hypopigmenting agent, or an anti-inflammatory agent.
Claims (20)
2. The cosmetic composition of claim 1 , wherein the 3,6-anhydro-L-galactose is prepared by:
preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and
allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
3. The cosmetic composition of claim 2 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid.
4. The cosmetic composition of claim 2 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1.
5. The cosmetic composition of claim 2 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3.
7. The pharmaceutical composition of claim 6 , wherein the skin pigmentation disease is locally advanced due to an increase in synthesis of a melanin pigment, and is at least one selected from the group consisting of chloasma, freckles, lentigo, nevi, pigmentation caused by use of drugs, post-inflammatory pigmentation, and hyperpigmentation occurring on dermatitis.
8. The pharmaceutical composition of claim 6 , wherein the 3,6-anhydro-L-galactose is prepared by:
preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and
allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
9. The pharmaceutical composition of claim 8 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid.
10. The pharmaceutical composition of claim 8 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1.
11. The pharmaceutical composition of claim 8 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3.
13. The pharmaceutical composition of claim 12 , wherein the 3,6-anhydro-L-galactose is prepared by:
preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and
allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
14. The pharmaceutical composition of claim 13 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid.
15. The pharmaceutical composition of claim 13 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1.
16. The pharmaceutical composition of claim 13 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3.
17. A method for preparing 3,6-anhydro-L-galactose, comprising:
preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and
allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.
18. The method of claim 17 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid.
19. The method of claim 17 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1.
20. The method of claim 17 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120005716 | 2012-01-18 | ||
KR10-2012-0005716 | 2012-01-18 | ||
PCT/KR2013/000423 WO2013109096A1 (en) | 2012-01-18 | 2013-01-18 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
KR10-2013-0005704 | 2013-01-18 | ||
KR1020130005704A KR101525298B1 (en) | 2012-01-18 | 2013-01-18 | Method for preparing 3,6-Anhydro-l-galactose and use of the 3,6-Anhydro-l-galactose |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/000423 A-371-Of-International WO2013109096A1 (en) | 2012-01-18 | 2013-01-18 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/352,073 Division US20170071841A1 (en) | 2012-01-18 | 2016-11-15 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150216778A1 true US20150216778A1 (en) | 2015-08-06 |
Family
ID=48995382
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/373,274 Abandoned US20150216778A1 (en) | 2012-01-18 | 2013-01-18 | Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof |
US15/352,073 Abandoned US20170071841A1 (en) | 2012-01-18 | 2016-11-15 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
US15/689,840 Active US10071041B2 (en) | 2012-01-18 | 2017-08-29 | Method for preparing 3,6-anhydro-L-galactose, and use thereof |
US16/100,337 Active US10639261B2 (en) | 2012-01-18 | 2018-08-10 | Method for preparing 3,6-anhydro-L-galactose, and use thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/352,073 Abandoned US20170071841A1 (en) | 2012-01-18 | 2016-11-15 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
US15/689,840 Active US10071041B2 (en) | 2012-01-18 | 2017-08-29 | Method for preparing 3,6-anhydro-L-galactose, and use thereof |
US16/100,337 Active US10639261B2 (en) | 2012-01-18 | 2018-08-10 | Method for preparing 3,6-anhydro-L-galactose, and use thereof |
Country Status (4)
Country | Link |
---|---|
US (4) | US20150216778A1 (en) |
JP (2) | JP6022603B2 (en) |
KR (2) | KR101525298B1 (en) |
CN (2) | CN111544437A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108884120A (en) * | 2016-04-04 | 2018-11-23 | 高丽大学校产学协力团 | For the novel method by using microorganism purifying 3,6- dehydration-L- galactolipin |
CN108883121A (en) * | 2015-10-16 | 2018-11-23 | 高丽大学校产学协力团 | 3,6- anhydrous-L- galactolipins are used for the purposes of pre- anti-caries |
CN109072268A (en) * | 2016-01-19 | 2018-12-21 | 高丽大学校产学协力团 | Heat-resisting agarase and the monosaccharide preparation method for using this heat-resisting agarase |
WO2018226758A3 (en) * | 2017-06-05 | 2019-01-10 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage |
US11268114B2 (en) | 2016-12-07 | 2022-03-08 | Korea University Research And Business Foundation | Method for producing anhydrous galactose derived from seaweed |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101641173B1 (en) | 2014-10-01 | 2016-07-21 | 고려대학교 산학협력단 | Method for improving production yield of monomeric sugars using pretreatment of agar by buffer solution |
WO2016154277A1 (en) * | 2015-03-24 | 2016-09-29 | Advanced Aesthetic Technologies, Inc. | Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems |
KR102048612B1 (en) * | 2017-03-28 | 2019-11-26 | 어업회사법인 주식회사 제주아가 | Paste agar and Preparing Method for the Same |
KR102032799B1 (en) * | 2017-11-16 | 2019-10-17 | 고려대학교 산학협력단 | Method for producing agarotriose and prebiotics use thereof |
KR102070153B1 (en) * | 2017-12-20 | 2020-01-28 | (주)밀양한천 | Beverage Composition comprising Normal Temperature Soluble and Non coagulable Agar-Agar |
CN109125179B (en) * | 2018-10-15 | 2021-04-30 | 华侨大学 | Antioxidant soothing moisturizing cream composition and preparation method thereof |
CN111374898A (en) * | 2018-12-28 | 2020-07-07 | 西安臻瑞生物科技有限公司 | Skin cream for removing chloasma and preparation method thereof |
CN110669149B (en) * | 2019-09-25 | 2021-11-12 | 中国海洋大学 | Galacto-oligosaccharide and derivative and application thereof in medicines or health products for improving mitochondrial function and preventing and treating insulin resistance related diseases |
KR102608602B1 (en) * | 2020-11-27 | 2023-12-01 | (주)헬스코치생명공학 | Composition for improving skin wrinkle by ultraviolet rays using AHG |
CN114836405B (en) * | 2022-04-08 | 2023-07-04 | 江南大学 | Agarase mutant with improved thermal stability and application thereof |
KR102537335B1 (en) * | 2022-08-10 | 2023-05-26 | 경북대학교 산학협력단 | Composition for immunosuppression comprising l-ahg |
WO2024227119A2 (en) * | 2023-04-28 | 2024-10-31 | Biohaven Therapeutics Ltd. | Bifunctional small molecules to target the selective degradation of circulating proteins |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0265788A (en) * | 1988-08-30 | 1990-03-06 | Japanese Res & Dev Assoc Bio Reactor Syst Food Ind | Production of agar oligosaccharide |
EP0748339B1 (en) | 1994-03-04 | 2004-01-14 | Sports Eze Limited | The manufacture of and uses for low molecular weight agars and agaroids |
EA004148B1 (en) * | 1997-11-11 | 2004-02-26 | Такара Сузо Ко., Лтд | Pharmaceutical composition based on 3,6-anhydrogalactopyranose and/or derivatives thereof, and/or derivatives, and/or soluble saccharide containing the above compound, use of said composition and ingredients thereof, food product comprising said composition and use of said product |
TWI244484B (en) * | 1998-06-09 | 2005-12-01 | Takara Bio Inc | Pharmaceutical composition containing oxy-containing hexacyclic compound |
AU2005300A (en) | 1999-01-20 | 2000-08-07 | Takara Shuzo Co., Ltd. | Medicinal compositions |
JP3916400B2 (en) * | 1999-02-23 | 2007-05-16 | タカラバイオ株式会社 | α-Agarase and production method thereof |
US6630330B1 (en) * | 2000-08-02 | 2003-10-07 | Biopolo S.C.A.R.L. | Ascorbic acid production from yeast |
ATE392477T1 (en) * | 2001-02-27 | 2008-05-15 | Takara Bio Inc | AGARASE AND GENE FOR IT |
KR20100040438A (en) * | 2008-10-10 | 2010-04-20 | 고려대학교 산학협력단 | A novel agarase and an enzymatic production method of agarooligosaccharide from agarose using the same |
CN102405282B (en) * | 2009-03-27 | 2014-02-12 | 高丽大学校产学协力团 | Novel alpha-neoagarobiose hydrolase, and method for obtaining monosaccharide using same |
KR101087265B1 (en) | 2009-12-23 | 2011-11-29 | 고려대학교 산학협력단 | Production method of 3,6-anhydro-L-galactose and galactose using coenzyme of Saccharopagus degrudans 2-40 and quantification of 3,6-anhydro-L-galactose |
KR101203504B1 (en) | 2010-04-09 | 2012-11-21 | 경희대학교 산학협력단 | Composition for Wrinkle-Care or Skin Whitening Containing Fermentation Liquor of Extract from Stewartia koreana |
KR101212106B1 (en) * | 2010-04-16 | 2012-12-13 | 제주대학교 산학협력단 | A beta-agarase and a use of the same |
KR101744341B1 (en) * | 2010-06-15 | 2017-06-09 | 삼성전자주식회사 | Composition for Measuring of 3,6-L-AHG Transferase Activity, Method for Measuring of 3,6- L-AHG Transferase Activity Using the Same, and Composition for quantitative analysis of 3,6- L-AHG |
KR101327248B1 (en) * | 2011-07-26 | 2013-11-13 | 고려대학교 산학협력단 | Novel marine bacterium of metabolizing 3,6-anhydro-L-galactose and use of the same |
-
2013
- 2013-01-18 CN CN202010514591.XA patent/CN111544437A/en active Pending
- 2013-01-18 JP JP2014553259A patent/JP6022603B2/en active Active
- 2013-01-18 KR KR1020130005704A patent/KR101525298B1/en active Active
- 2013-01-18 US US14/373,274 patent/US20150216778A1/en not_active Abandoned
- 2013-01-18 CN CN201380007372.0A patent/CN105745329B/en active Active
-
2015
- 2015-02-25 KR KR1020150026300A patent/KR101573651B1/en active Active
-
2016
- 2016-08-05 JP JP2016154493A patent/JP2016188251A/en active Pending
- 2016-11-15 US US15/352,073 patent/US20170071841A1/en not_active Abandoned
-
2017
- 2017-08-29 US US15/689,840 patent/US10071041B2/en active Active
-
2018
- 2018-08-10 US US16/100,337 patent/US10639261B2/en active Active
Non-Patent Citations (6)
Title |
---|
Chirapart, A., Ohno, M., Ukeda, H., Sawamura, M., Kusunose, H. (1997) Effects of partial acid hydrolysis on physical and chemical properties of agar from a newly reported Japanese agarophyte (Gracilariopsis lemaneiformis). Journal of Applied Phycology, vol. 9, p. 73-76. * |
Ducatti, D.R.B., Colodi, F.G., Gonçalves, A.G., Duarte, M.E.R., Noseda, M.D. (2011) Production of agaro- and carra-oligosaccharides by partial acid hydrolysis of galactans. Brazilian Journal of Pharmacognosy, vol. 21, no. 2, p. 296-304. * |
Kim, H.T., Lee, S., Lee, D., Kim, H.-S., Bang, W.-G., Kim, K.H., Choi, I.-G. (2010) Overexpression and molecular characterization of Aga50D from saccharophagus degradans 2-40: an exo-type Ã-agarase producing neoagarobiose. Applied Microbiology and Biotechnology, vol. 86, p. 227-234. * |
Munegumi, T. (2013) Where is the Border Line between Strong Acids and Weak Acids? World Journal of Chemical Education, vol. 1, no. 1, p. 12-16. * |
Rees, D.A. (1961) Enzymic Synthesis of 3:6-Anhydro-L-Galactose within Porphyran from L-Galactose 6-Sulphate Units. Biochemical Journal, vol. 81, p. 347-352. * |
Yun, E.J., Shin, M.H., Yoon, J.-J., Kim, Y.J., Choi, I.G., Kim, K.H. (2011) Production of 3,6-anhydro-L-galactose from agarose by agarolytic enzymes of Saccharophagus degradans 2-40. Process Biochemistry, vol. 46, p. 88-93. Available online 26 July 2010. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883121A (en) * | 2015-10-16 | 2018-11-23 | 高丽大学校产学协力团 | 3,6- anhydrous-L- galactolipins are used for the purposes of pre- anti-caries |
CN109072268A (en) * | 2016-01-19 | 2018-12-21 | 高丽大学校产学协力团 | Heat-resisting agarase and the monosaccharide preparation method for using this heat-resisting agarase |
US10655118B2 (en) | 2016-01-19 | 2020-05-19 | Korea University Research And Business Foundation | Heat-resistant agarase and monosaccharide production method using same |
CN108884120A (en) * | 2016-04-04 | 2018-11-23 | 高丽大学校产学协力团 | For the novel method by using microorganism purifying 3,6- dehydration-L- galactolipin |
US11118202B2 (en) | 2016-04-04 | 2021-09-14 | Korea University Research And Business Foundation | Method for purifying and obtaining 3,6-anhydro-L-galactose using microorganisms |
US11268114B2 (en) | 2016-12-07 | 2022-03-08 | Korea University Research And Business Foundation | Method for producing anhydrous galactose derived from seaweed |
WO2018226758A3 (en) * | 2017-06-05 | 2019-01-10 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage |
Also Published As
Publication number | Publication date |
---|---|
CN105745329A (en) | 2016-07-06 |
CN105745329B (en) | 2020-07-03 |
JP2015505323A (en) | 2015-02-19 |
US10071041B2 (en) | 2018-09-11 |
US20170360671A1 (en) | 2017-12-21 |
JP2016188251A (en) | 2016-11-04 |
KR20150039159A (en) | 2015-04-09 |
KR101573651B1 (en) | 2015-12-02 |
CN111544437A (en) | 2020-08-18 |
US20170071841A1 (en) | 2017-03-16 |
US20180344607A1 (en) | 2018-12-06 |
JP6022603B2 (en) | 2016-11-09 |
KR20130085017A (en) | 2013-07-26 |
US10639261B2 (en) | 2020-05-05 |
KR101525298B1 (en) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10639261B2 (en) | Method for preparing 3,6-anhydro-L-galactose, and use thereof | |
JP5588474B2 (en) | Composition for promoting collagen and / or hyaluronic acid production | |
US11433013B2 (en) | Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use thereof | |
KR101088069B1 (en) | Novel Use of Panduratin Derivatives or Caemperia Pandurata Extract Containing the Same | |
CN118055940A (en) | Peptides having hair loss preventing or hair growth promoting activity and uses thereof | |
KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
WO2013109096A1 (en) | Method for preparing 3,6-anhydro-l-galactose, and use thereof | |
KR102032799B1 (en) | Method for producing agarotriose and prebiotics use thereof | |
EP4197522A1 (en) | Composition comprising galactinol and use thereof | |
KR102476671B1 (en) | Composition for skin conditioning comprising Scutellaria baicalensis Georgi extract | |
KR20220027342A (en) | Composition for controlling melanin production comprising plant-derived oligonucleotides | |
KR102532713B1 (en) | Novel Saccharomyces cerevisiae strain and use thereof | |
KR102741555B1 (en) | Composition for improving skin wrinkle or whitening comprising mitochondria-derived peptide with high skin permeability | |
JP2010077041A (en) | Bleaching ingredient and skin cosmetic | |
JP2004059480A (en) | Hyaluronic acid production promoter | |
EP3895687A1 (en) | Composition comprising allulose as active ingredient for skin whitening | |
KR101923062B1 (en) | Composition including neoagarooligosaccharide for preventing, improving or treating osteoporosis | |
JP2023001563A (en) | skin sensation activator | |
KR20250062172A (en) | Composition for Skin Whitening Comprising Extract or Fraction of Silvetia Siliquosa as an Active Ingredient | |
KR20240023247A (en) | Compositions for promoting wound healing or skin regeneration | |
KR20230066692A (en) | Wrinkle-improving composition including compound separated from kaempferia parviflora extract | |
KR20250062168A (en) | Composition for Skin Whitening Comprising Extract or Fraction of Sargassum confusum as an Active Ingredient | |
KR20250021175A (en) | Composition for skin whitening comprising Citrulluside T | |
KR101118572B1 (en) | Hydroquinone-beta-d-fructoside and composition comprising the same | |
KR101289811B1 (en) | Composition for anti-wrinkle comprising an extract of Prunus persica var. davidiana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, KYOUNG HEON;CHOI, IN GEOL;KANG, NAM JOO;AND OTHERS;SIGNING DATES FROM 20140611 TO 20140612;REEL/FRAME:033380/0660 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |